WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 571059
CAS#: 1430634-79-9
Description: AB-002 is a homologue of AB-001, which is a cannibimimetic. It is a CB (cannabinoid) receptor ligand that governs the cannabimimetic potency. It is derived from adamantane and is less potent than other ligands which can induce significant hypothermic and bradycardic effects. Its role in binding CB receptors may be useful in therapeutic discovery for relief against MS, particularly when studying selective CB2 agonists.
MedKoo Cat#: 571059
Name: AB-002
CAS#: 1430634-79-9
Chemical Formula: C25H33NO
Exact Mass: 363.2562
Molecular Weight: 363.55
Elemental Analysis: C, 82.60; H, 9.15; N, 3.85; O, 4.40
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 1430634-79-9 (AB-001) 1345973-49-0 (AB-002)
Synonym: AB-002; AB 002; AB002
IUPAC/Chemical Name: 2-(adamantan-1-yl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-one
InChi Key: BRHHDIPEHOKFET-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H33NO/c1-2-3-6-9-26-17-22(21-7-4-5-8-23(21)26)24(27)16-25-13-18-10-19(14-25)12-20(11-18)15-25/h4-5,7-8,17-20H,2-3,6,9-16H2,1H3
SMILES Code: O=C(CC12CC3CC(C2)CC(C3)C1)C4=CN(CCCCC)C5=C4C=CC=C5
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 363.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Banister SD, Wilkinson SM, Longworth M, Stuart J, Apetz N, English K, Brooker L, Goebel C, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M. The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci. 2013 Jul 17;4(7):1081-92. doi: 10.1021/cn400035r. Epub 2013 Apr 17. PubMed PMID: 23551277; PubMed Central PMCID: PMC3715837.
1: Shi Y, Duan YH, Ji YY, Wang ZL, Wu YR, Gunosewoyo H, Xie XY, Chen JZ, Yang F, Li J, Tang J, Xie X, Yu LF. Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis. J Med Chem. 2017 Aug 3. doi: 10.1021/acs.jmedchem.7b00724. [Epub ahead of print] PubMed PMID: 28726401.
The endocannabinoid system consists of at least two cannabinoid (CB) receptors, namely, the CB1 and CB2 receptors. Stimulation of the CB1 receptor leads to modulation of feeding behavior, through a proposed mechanism of N-type and P/Q-type calcium channel blockade while activating the inwardly rectifying potassium channels, implicating an important role for CB1 receptor in obesity and metabolic disorders through release of neuromodulators. However, the usage of the drugs may have severe side effects on the CNS such as depression, anxiety, and suicidal thoughts. Selective CB2 agonists represent an attractive therapeutic strategy for the treatment of a variety of diseases such as MS without psychiatric side effects mediated by the CB1 receptor.
